Presenter: Irina Rapoport
Mentor: Andy Berglund
AM Poster Presentation
Poster 37
Myotonic dystrophy is the most common form of adult-onset muscular dystrophy. DM type 1 is caused by aberrantly expanded CTG repeats in the 3’ untranslated region of the DMPK gene. Upon transcription, toxic RNA CUG repeats are formed, which sequester Mbnl proteins, causing abnormal splicing in cells. Some of these abnormal splicing events have been shown to lead to the disease symptoms. Small molecules that release Mbnl sequestration from the toxic RNA could alleviate disease symptoms. I am crystallizing CUG-containing RNA constructs with and without small molecules. Crystal structures would provide direct evidence of where and how the small molecules bind the toxic RNA. Before crystallography, the RNA is deprotected, purified by HPLC, resuspended in buf- fer and annealed. Using Natrix crystallization screens, I test a wide array of conditions for crystal formations. Then, I scale up and vary the most favorable conditions to obtain bigger crystals. Two different RNA constructs, containing three CUG repeats, have crystal- lized well without small molecules under several conditions. A third RNA construct, with two CUG repeats, formed crystals with a small molecule called JFA12046. To screen for additional small molecules with the ability to disrupt the MBNL-CUG complex, we are running competitive electrophoretic mobility shift assays. Long-term, efficiently designed small molecules could be used as therapeutic agents to treat myotonic dystrophy and other diseases with similar molecular mechanisms.